U.S. Venture Fund Invests Millions In Chinese Biotech
This article was originally published in PharmAsia News
Executive SummaryA U.S. venture-capital company says it has invested $15 million in the Chinese biotech, Jinsite Science and Technology, according to a source. Kleiner, Perkins Caufield & Byers signed the deal as the first of more than half a dozen investments the firm expects to make in China this year. Jinsite is a subsidiary of GenScript, a U.S. company offering outsourcing services for biological and pharmaceutical research. KPCB began investing in China two years ago and now is one of the largest venture-capital funds in the United States. (Click here for more
You may also be interested in...
Analyzing Quality Data Is Essential. Here’s What One Expert Says Your Firm Should Do To Stay In FDA’s Good Graces
Device makers should make sure they have adequate resources to analyze quality data they take in so they can prevent the recurrence of nonconforming products, processes and procedures. That’s just one nugget of advice from former FDA investigations branch director Ricki Chase, who explains why collecting and properly handling such data is critical to complying with agency expectations in this Medtech Insight Q&A interview.
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.